Cannliv is Making a Difference

MD Anderson Cancer Center, CANNLIV CBD, cancer research, cannabidol

In early May of this year, CANNLIV proudly announced a new partnership with one of the most esteemed cancer research institutions in the world, MD Anderson. For 75 years the MD Anderson Cancer Center at the University of Texas has provided care, research and new innovations to cancer patients. Their caring and open-minded approach recognized the potential of cannabinoids like cannabidiol (CBD) as a therapy for cancer patients which led to the search for a source of the highest quality CBD in the world.

With CANNLIV’s highest quality organic CBD extracted from hemp, a variety of the Cannabis sativa plant, MD Anderson will research the different ways that CBD can help further efforts to eliminate cancer in the world. CBD has shown tremendous promise as an anti-inflammatory which can help cancer patients suffering from neuropathic pain. Some studies have even shown that CBD can slow certain cancer cells’ growth or even kill cancer cells. We are delighted to be working with MD Anderson and can only hope that CANNLIV CBD is the catalyst for new breakthroughs in cancer treatment.

Cannliv announced a Strategic Alliance with The University of Texas MD Anderson Cancer Center for pre-clinical research of the effects of Cannabinoids on cancer cells and developing therapies for treating cancers based on this research. Under the direction of Richard Ford, MD, Ph.D. and Lan Pham, Ph.D., Department of Hematopathology, Division of Pathology and Laboratory Medicine at MD Anderson, this 5-year agreement will explore the potential for cancer treatments using naturally occurring Cannabinoids that contain no tetrahydrocannabinol (THC). As part of the alliance, Cannliv, a Denver-based Hemp Product Research and Development Company specializing in emerging U.S. and International Markets, will provide proprietary Cannabinoid products, immutable ledger integrated Enterprise Resource Planning (ERP) solutions, and full access to its vast network of Cannabinoid knowledge.

“We could not be more pleased and humbled by the possibilities of this relationship,” stated John David Carrasco, Cannliv President and CEO. “This collaboration with MD Anderson allows us to investigate the effects of Cannabinoids on cancer cells in ways never thought possible.” He went on to say that “by implementing the latest in technology, we will create a truly transparent Chain of Custody to ensure patients and consumers know exactly how products are developed, the results and data from the research, and what they are putting in their bodies. Most importantly this allows us to seamlessly integrate patient data with treatment protocols in order to ensure best possible outcomes.”

Cannliv Colorado LLC is a privately-owned company based in Denver Colorado. Cannliv has developed products with Cannabinoids since October 2015 along with their solution to assist companies to achieve an immutable compliance level within the medical cannabis space using Ledger technology. Cannliv also has divisions in South America since August 2016. For additional information or collaboration inquiries, contact Wade Leach, Investor and Relations Consultant for Cannliv.

With such strong restrictions on cannabinoids we believe this research will open doors for an even more rigorous scientific study of cannabis. Cannabidiol and other cannabinoids found in the Cannabis sativa plant have shown a great deal of promise in treating all sorts of diseases and conditions. If CANNLIV CBD can affect the movement to rid the world of cancer it will be a crowning achievement for this company. We look forward to keeping you updated on the MD Anderson Cancer Center’s research with our highest grade CBD.
read more at newswire.com

The First Of It’s Kind, Camp Green Rush, Essential For All Cannabis Advocates

Cannliv Gears up for Camp Green Rush 2018
Jan 19th-22nd,2018
Canyon Creek Retreat Center in Lake Hughes, CA
 
Camp Green Rush will be connecting some of the most respected and established cannabis advocates and entrepreneurs together in a 4-day, 3-night upscale camping retreat concentrated on education, wellness, community building, and recreation in a luxurious 82-acre facility.


Register on their website with just a few clicks. Register here
Camp Green Rush is the brainchild of talk radio duo Tilo Murray and Julian Michael, collectively known as “Mayhem and Token.” They are proud advocates of legal cannabis and are more than thrilled to be able to provide such a unique opportunity for professionals and enthusiasts to come together, learn, and celebrate all while propelling the industry forward.
Camp Green Rush will be hosting experts like:
Tracy Ryan, CEO of CannaKids
Luke Patterson Founding President of Budbo/Budbo Token
Jason Beck, Owner of Alternative Herbal Health Services
Scott Page, CEO of Ignited Network: Pink Floyd saxophonist, brand expert, and technologist
See the rest of the speakers and session leaders here.
 
John David Carrasco to speak at Camp Green Rush
 

Cannliv CEO, John David will be speaking at the camp on Cannliv’s Wellness program and relationship with Budbo.  John David looks forward to experiencing other wellness concepts and ideas that he can incorporate into his own life.
As, he prepares for this unique event he believes, “Camp Green Rush and Cannliv line up well in our efforts to cultivate, educate and facilitate which is part of our mission.”
“As CEO, I am pleased to have our marketing team traveling with us.  We will document our travel, have impromptu interviews where I as CEO, will interview our marketing staff to encourage their development in working with other team members at CGR. “
(learn more about Cannliv)
 

Not just business, a retreat organized for wellness and fun

Camp Green Rush an excellent networking opportunity, it will feature an elevated camping experience providing:
Locally-sourced gourmet food prepared daily
Upscale cabins and yurts designed for adult comfort
Yoga classes, nature hikes, massages, aromatherapy, and other wellness experiences
Happy hours
Camp games and activities
Stephen Perkins of Jane’s Addiction leads a jam session starring surprise celebrities
National headlining comedians tell jokes by the fire
 
(Learn more about Camp Green Rush here.)

Camp Green Rush is currently discounting the remaining weekend passes. Sign up now and get a savings of $177
 
SIGN UP
 
 


 
 
 
 
 
Contact: campgreenrush@gmail.com
Learn about The Founders 
Mention you were referred by CANNLIV and receive a special gift at camp.

World Health Organization Declares Cannabis Compound CBD Safe.

The W.H.O declares CBD safe.
The World Anti-Doping Agency removed CBD from its 2018 prohibited substances list.
Cannliv Colorado LLC is now fully operational in Denver.
Cannliv connects the United States, South America, and Israel, setting exceptional standards in Hemp growth and exploration methods.
 
On December 14th, 2017, the World Health Organization (WHO), the international public health agency of the United Nations, officially supported cannabidiol (CBD), the relaxant compound of cannabis used in medical marijuana, stating, “not be internationally scheduled as a controlled substance.”
This news is fantastic for all CBD and Cannabis advocates throughout the world. As further research continues, we see many regions around the world-such as Israel, which has been called, “The Holy Land Of Medical Marijuana”-continually study the benefits and effects of Cannabis and the body.
Colorado has been a leader in the CBD research and development for years. There are, however, some adversities of Colorado. For a long time, the US Drug Enforcement Administration(DEA) has maintained that the non-psychoactive component of marijuana, cannabidiol, is a schedule I drug, classifying it as, “a drug that contains no trusted medical benefits and has a high potential for abuse.”
However, according to a preliminary report embraced by the WHO last week, the Expert Committee on Drug Dependence(ECDD) decided—and the WHO agreed—that clinical and pre-clinical studies of CBD have shown no evidence of potential abuse of the drug or experience any harms. Moreover, the experts have found plenty of indications that CBD has medical benefits, especially for treating epilepsy and that there’s “preliminary evidence” that CBD could be useful in treating Alzheimer’s disease, cancer, psychosis, Parkinson’s disease, and other severe conditions. Furthermore, the ECDD has declared that the current data “does not justify scheduling of cannabidiol.”
The WHO’s release also called for a fuller review of CBD in May 2018, when the ECDD will go through a more thorough review of cannabis and cannabis-related substances.
CBD and the Endocannabinoid System

CBD is thought to have a wide range of activities on the endocannabinoid system. When your body intakes CBD, it does not change the CB-receptors but instead interacts with other cannabinoid receptors that have been claimed to affect mood, appetite, pain, and inflammation.
Although researchers are still working out all of CBD’s functions, studies on animals and a small number of humans have found no evidence that it is toxic or addictive. It is a comparably safe compound that does not get the user “high” but helps regulate the endocannabinoid system. Further information is shown in the WHO report,
“There are two main cannabinoid (CB) receptors, CB1 which is primarily
located in the central nervous system with some expression in peripheral
tissues and CB2 receptors, which can be found in the periphery on cells with
immune function and in the gastrointestinal tract and at low densities in the
central nervous system.
       CBD does not appear to act directly at CB1 receptors, with a number of studies
reporting that there is no measurable response in binding assays. In studies
examining potential agonist effects at CB1 receptors, most find no effect, with
one report of a weak agonist and one of a weak antagonist effect, each at high
concentrations (>10uM). CBD also shows low affinity at CB2 receptors. [42]
       Across a range of measures in humans and animals, CBD had been shown to
have very different effects from those of THC. In mice, CBD failed to produce
the behavioral characteristics (e.g. suppression of locomotors activity,
hypothermia, antinociception) associated with CB1 activation, whereas THC
generated all of the effects which occur when CB1 is activated.”
(Published preliminary WHO report on CBD’s safety and benefits. [PDF])
Current standings on CBD

With the expanding data and the increasing acceptance of marijuana in the United States, CBD and other cannabis products are standing in the spotlight as the go-to medical alternative.
The World Anti-Doping Agency (WADA) removed CBD from its 2018 prohibited substances list. “Cannabidiol is no longer prohibited,” said WADA in its September 29 statement. However, without federal sanction and regulation, many CBD products—especially those sold online—can be mislabeled.
Not all CBD products are the same

Cannliv’s South America Hemp Forest: Cannliv’s core values begin with quality growth, superior extraction, and purity from the root. 
While CBD itself is safe and found to be helpful for many users, industry experts have warned that not all cannabis extracts are created equally, purely, or with the same methods of extraction.
Cannliv connects the United States, South America, and Israel, setting exceptional standards in hemp growth and exploration methods. Our growth and extraction methods have changed the hemp industry and surpassed current standards.
We believe in the cultivation of medical hemp for the production of natural, clean and user-friendly cannabinoid products that are crafted with the purest ingredients for a truly consistent and reliable source of hemp extract. Our scientists perform extensive cannabinoid profiling of our products, guaranteeing our hemp is microbial- and pathogen-free. This comprehensive testing sets the standard for what patients should expect in quality and safety of their medicine.

(Part of Cannliv South America team taking quality control to a hands-on level)


We are proud to announce that Cannliv Colorado LLC is now fully operational in Denver.